Q&A: What have been the results of using everolimus (Afinitor) to treat metastatic breast cancer? In patient with metastatic breast cancer who had received prior hormonal therapy, the addition of everolimus to second line hormonal treatment with exemestane or tamoxifen more than doubled the progression-free interval (the duration of control of metastatic breast cancer) while preserving the quality of life of the patients. There was also a significant increase in response rate and clinical benefit rate. For information about participating in a clinical trial testing hormonal therapy with and without everolimus (Afinitor), contact the CTSU (Cancer Trials Support Unit) of the National Cancer Center at888-823-5923. The folks at CTSU can tell you which sites (physician offices or hospitals) have the study open in their area and you could be referred to an oncologist at one of those institutions. As well, the NCT (National Clinical Trials) web page provides more information at: clinicaltrials.gov/show/NCT01674140 talkabouthealth/what-have-been-the-results-of-using-everolimus-afinitor-to-treat-metastatic-breast-cancer
Posted on: Sun, 13 Jul 2014 13:00:01 +0000